Drug intelligence / Profile preview

SPH6516

Development stage: Phase 1
Lead developer: Shanghai Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SPH6516 is an investigational small molecule inhibitor targeting cyclin-dependent kinases 4 and 6 (CDK4/6). It is being developed by Shanghai Pharmaceuticals Holding for the treatment of advanced solid tumors. The drug acts by inhibiting CDK4 and CDK6, which are key regulators of cell cycle progression, thereby potentially suppressing tumor growth. Phase 1 clinical trials have been completed to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[1][2].

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on SPH6516.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH6516.

Explore the full profile